Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru

August 19, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra-Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E) Mumbai - 400 051 Dalal Street, Mumbai – 400 001 Symbol: STAR Scrip code: 532531 Dear Madam/ Sir, Sub: Press Release Please find attached Press Release issued by the Company titled: “Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru” Thanks & Regards, For Strides Pharma Science Limited, Manjula Ramamurthy Company Secretary ICSI Membership No. A30515 Encl. As above Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India |Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com Press Release 19 August 2026 Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru Bangalore, India, 19 August 2026 - Strides Pharma Science Limited (Strides) today announced that its flagship manufacturing facility in Bengaluru, India, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA), indicating the successful closure of the inspection conducted at the facility. The USFDA had conducted a current Good Manufacturing Practices (cGMP) inspection of the facility from May 12 to May 20, 2026. As previously disclosed to the stock exchanges on May 20, 2026, the inspection concluded with the issuance of a Form 483 that contained five observations. The Company submitted a comprehensive response addressing all observations within the stipulated timeline. Based on the Company's response and the corrective and preventive actions implemented, the USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI) and has issued the Establishment Inspection Report (EIR), thereby concluding the inspection. The facility is Strides' flagship manufacturing site and serves regulated and other international markets. The facility manufactures a broad portfolio of pharmaceutical dosage forms, including tablets, capsules and oral liquids, supporting both existing commercial products and future growth opportunities. The successful closure of the inspection further strengthens Strides' regulatory track record and reinforces the Company's commitment to supplying high-quality pharmaceutical products to patients across global markets. About Strides Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com. For further information, please contact: Investor Relations Corporate Communication Vikesh Kumar: Group CFO Pallavi Panchmatia: +91 80 6784 0193 investor-relations@strides.com Pallavi.panchmatia@strides.com Saurabh Ambaselkar: +91 99609 31220 Abhilash Mukherjee: +91 89044 28907 saurabh.ambaselkar@strides.com Abhilash.Mukherjee@strides.com Adrita Chatterjee: +91 92842 40813 Strides Pharma Science Limited adrita.chatterjee@adfactorspr.com Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076 1 Strides Pharma Science Ltd.